Prediction of Cancer Incidence and Mortality in Korea, 2016

Kyu-Won Jung; Young-Joo Won; Chang-Mo Oh; Hyun-Joo Kong; Hyunsoon Cho; Jong-Keun Lee; Duk Hyoung Lee; Kang Hyun Lee

doi:10.4143/crt.2016.092

Articles

Page Path: HOME > Cancer Res Treat > Volume 48(2); 2016 > Article

Special Article Prediction of Cancer Incidence and Mortality in Korea, 2016: Kyu-Won Jung, MS^1,2, Young-Joo Won, PhD^1,2,3,, Chang-Mo Oh, MD, PhD^1,2, Hyun-Joo Kong, MS^1,2, Hyunsoon Cho, PhD^1,2,3, Jong-Keun Lee, MD, PhD^1,2, Duk Hyoung Lee, MD, PhD^2,3, Kang Hyun Lee, MD, PhD¹; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2016;48(2):451-457.
DOI: https://doi.org/10.4143/crt.2016.092
Published online: March 25, 2016

¹The Korea Central Cancer Registry, National Cancer Center, Goyang, Korea

²National Cancer Control Institute, National Cancer Center, Goyang, Korea

³Department of Cancer Control and Policy, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

Correspondence: Young-Joo Won, PhD The Korea Central Cancer Registry, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
Tel: 82-31-920-2015 Fax: 82-31-920-2179 E-mail: astra67@ncc.re.kr

• Received: March 1, 2016 • Accepted: March 25, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

16,661 Views
328 Download
54 Web of Science
54 Crossref
52 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose:
To estimate of Korea’s current cancer burden, this study aimed to report on projected cancer incidence and mortality rates for the year 2016.
Materials and Methods:
Cancer incidence data from 1999 to 2013 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2014 were acquired from Statistics Korea. Cancer incidence in 2016 was projected by fitting a linear regression model to observed age-specific cancer incidence rates against observed years, then multiplying the projected age-specific rates by the age-specific population. The Joinpoint regression model was used to determine at which year the linear trend changed significantly.
Results:
A total of 254,962 new cancer cases and 75,172 cancer deaths are expected to occur in Korea in 2016. The five leading primary cancer incident sites in 2016 were estimated colorectal, stomach, lung, liver and thyroid cancer in men; thyroid, breast, colorectal, stomach, and lung cancer in women.
Conclusion:
Currently cancer is one of the foremost public health concerns in Korea. Although cancer rates are anticipated to decrease the nation’s cancer burden will continue to increase as the population ages.
Key words: Incidence, Mortality, Neoplasms, Forecasting, Korea, 2016

Introduction

As the leading cause of death in Korea [1], cancer has been the country’s main public health concern since 1983. Over 224,000 patients were newly diagnosed with cancer in Korea, and one in four deaths is due to cancer [2]. Although the cancer registration system in Korea is highly efficient and it can provide nationwide cancer statistics within a relatively brief period, a lag time of at least 2 years is required to collect, compile, and analyze the data of a specific year. For planning and implementation of comprehensive cancer control programs, it is important to assess the number of new cases and deaths that are expected to occur during the current year. In this study, we report the projected cancer incidence and mortality for the year 2016 based on data from the 1990s through 2014.

Materials and Methods

The Korean Ministry of Health and Welfare initiated a nationwide, hospital-based cancer registry, the Korea Central Cancer Registry (KCCR), in 1980. The history, objectives, and activities of the KCCR have been documented in detail elsewhere [3]. Incidence data from 1999 to 2013 were obtained from the Korea National Cancer Incidence Database. Cancer cases were classified according to the International Classification of Diseases for Oncology, 3rd edition [4], and converted according to the International Classification of Diseases, 10th edition (ICD-10) [5]. Mortality data from 1993 to 2014 were acquired from Statistics Korea [1]. The cause of death was coded and classified according to ICD-10 [5].

The cancer sites included in this study were (1) all cancers combined and (2) the 24 common cancers as follows: lip, oral cavity, and pharynx (C00-C14), esophagus (C15), stomach (C16), colon and rectum (C18-C20), liver and intrahepatic bile duct (liver) (C22), gallbladder and other parts of the biliary tract (gallbladder) (C23-C24), pancreas (C25), larynx (C32), lung and bronchus (lung) (C33-C34), breast (C50), cervix uteri (C53), corpus uteri (C54), ovary (C56), prostate (C61), testis (C62), kidney (C64), bladder (C67), brain and central nervous system (C70-C72), thyroid (C73), Hodgkin lymphoma (C81), non-Hodgkin lymphoma (C82-C85, C96), multiple myeloma (C90), leukemia (C91-C95), and others.

Population data from 1993 to 2015 were obtained from the resident registration population, reported by Statistics Korea. Data on the mid-year population, as of July 1 of the respective year, were analyzed. For the year 2016, however, we used population data as of December 31, 2015, because mid-2015 resident registration population data were not yet available at the time of analysis.

Due to the time required for data collection, compilation, quality control, and analysis, incidence and mortality data for a specific year are usually available 2-3 years later. Therefore, to provide an estimate of the nation’s current cancer burden, we attempted to project, the expected number of new cancer cases and deaths in Korea for 2016. Linear regression models [6] were used to assess the time trends and projections. A simple linear or log-linear model of age-specific rates provide a good fit to the data, and it gives accurate predictions over a short time span [7]. Based on observed cancer incidence data from 1999 to 2013, a linear regression model was fitted to the age-specific rates by 5-year age groups against the observed years.

To predict the cancer incidence and mortality in 2016, we first performed a Joinpoint regression analysis on the data available to detect the year when significant changes occurred in cancer trends according to sex and cancer site. A Joinpoint regression describes changes in data trends by connecting several different line segments on a log scale at “joinpoints.” This analysis was performed using the Joinpoint software (ver. 4.0.1, http://surveillance.cancer.gov/joinpoint) from the Surveillance Research Program of the US National Cancer Institute [8]. We chose the number of joinpoints to ensure that there would be at least five data points between consecutive joinpoints. However, for thyroid cancer, which has recently shown significant decreasing trends, we selected three joinpoints, although the last segment had only three data points.

We summarized the results by using crude rates (CRs) and age-standardized rates (ASRs) of cancer incidence and mortality. ASRs were standardized using the world standard population [9] and expressed as rates per 100,000 persons.

Results

1. Incidence

A total of 254,962 new cancer cases are anticipated in 2016 (Table 1, Fig. 1), with more male (n=131,224) than female (n=123,738) cancer patients expected in the coming year.

The projected CRs per 100,000 of all sites combined in 2016 are projected to be 511.2 and 482.3 in men and women, respectively. The projected ASRs per 100,000 of all sites combined are 340.0 and 298.8, respectively (Table 2). In men, the five leading primary sites of cancer are expected to be the colon and rectum (CR, 91.2; ASR, 59.6), stomach (CR, 91.0; ASR, 59.0), lung (CR, 65.9; ASR, 42.3), liver (CR, 45.0; ASR, 29.1), and thyroid (CR, 43.7; ASR, 31.1), accounting for 65.9% of all new cancers in 2016.

In women, the five leading primary sites are expected to be the thyroid (CR, 133.5; ASR, 96.2), breast (CR, 79.3; ASR, 52.2), colon and rectum (CR, 56.8; ASR, 30.5), stomach (CR, 42.8; ASR, 23.5), and lung (CR, 31.8; ASR, 16.0), accounting for 71.4% of all new cancers (Fig. 1). Thyroid cancer alone is projected to account for approximately 27.7% (34,255 cases) of incident cases in women in 2016.

The five most common cancer sites expected in 2016 by sex and age group are shown in Table 3. Leukemia and thyroid cancer are expected to be the most common types of cancer in both genders for the 0-14 and 15-34 age groups. Stomach cancer is predicted to be the most prevalent in men aged 35-64 years, while lung cancer is expected to be more frequent in men aged 65 and over. Thyroid cancer is predicted to be the most common cancer in women 35-64 years of age, whereas colorectal cancer is expected to be the most prevalent in women aged 65 and over. These projections indicate that the incidences of stomach, lung, liver, colorectal, and prostate cancers will increase gradually with age for men. In women, the age-specific incidence rates of stomach, colorectal, liver, lung, and cervical cancers denote a rising trend in these cancers with age; however, the incidence of breast and thyroid cancer in women is expected to level off after the late 40s and early 50s, respectively (Fig. 2).

2. Mortality

It is estimated that 75,172 cancer deaths will occur in Korea in 2016 (Table 1, Fig. 1). The projected CRs per 100,000 of all sites combined in 2016 for men and women are projected to be 179.8 and 113.1, respectively, whereas the projected ASRs per 100,000 of all sites combined are expected to be 116.2 and 53.1, respectively (Table 4). The predicted five leading cancer sites causing mortality in men are predicted to be lung (CR, 49.4; ASR, 31.2), liver (CR, 30.6; ASR, 19.7), colon and rectum (CR, 20.1; ASR, 13.0), stomach (CR, 17.1; ASR, 11.0), and pancreas (CR, 11.2; ASR, 7.2). During the same period, lung cancer (CR, 18.8; ASR, 8.3) is projected to be the leading cancer site in women, causing mortality, followed by the colon and rectum (CR,13.9; ASR, 6.0), liver (CR, 10.9; ASR, 5.0), stomach (CR, 10.3; ASR, 4.5), and pancreas (CR, 10.2; ASR, 4.6).

The predicted age-specific mortality rates of the selected cancers for males and females in 2016 are shown in further detail in Fig. 3. When examined by age, Korean men and women aged 60 and over are expected to have the highest mortality rates from lung cancer.

Conclusion

A total of 254,962 new cancer cases and 74,096 cancer deaths are expected to occur in Korea during 2016. The colorectal cancer is predicted to the most common cancer among male for the first time, followed by stomach, lung, liver, and thyroid cancers. Lung, liver, colorectal, stomach, and pancreatic cancers are expected to be the most common causes of cancer deaths among men. In women, the five leading primary sites are expected to be the thyroid, breast, colorectal, stomach, and lung cancers are anticipated to be the most prevalent, while lung, colorectal, liver, stomach, and pancreatic cancers are projected to be the most common causes of cancer-related deaths.

Cancer is currently one of the foremost public health concerns in Korea. Although cancer rates are anticipated to decrease somewhat, but cancer burden will continue to increase with the aging of its population. The current projections of cancer incidence and mortality for 2016 represent an important resource for planning and evaluating cancer-control programs. As the estimates in this study are model-based, these results should be interpreted with caution.Cancer is currently one of the foremost public health concerns in Korea. Although cancer rates are anticipated to decrease somewhat, but cancer burden will continue to increase with the aging of its population. The current projections of cancer incidence and mortality for 2016 represent an important resource for planning and evaluating cancer-control programs. As the estimates in this study are modelbased, these results should be interpreted with caution.

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This work was supported by a research grant from the National Cancer Center (No. 1610200), Republic of Korea.

Fig. 1.

The 10 leading types of estimated new cancer cases and deaths by sex in 2016. (A) Estimated new cases. (B) Estimated deaths.

Fig. 2.

Projected age-specific incidences of major cancers during 2016 in Korea. (A) Male. (B) Female.

Fig. 3.

Projected age-specific mortality rates of major cancers during 2016 in Korea. (A) Male. (B) Female.

Table 1.

Estimated new cancer cases and deaths by sex during 2016 in Korea

Site	Estimated new cases			Estimated deaths
Site	Both sexes	Male	Female	Both sexes	Male	Female
All sites	254,962	131,224	123,738	75,172	46,155	29,017
Lip, oral cavity, and pharynx	3,236	2,363	873	1,059	775	284
Esophagus	2,335	2,137	198	1,199	1,125	74
Stomach	34,331	23,355	10,976	7,054	4,402	2,652
Colon and rectum	37,968	23,406	14,562	8,715	5,147	3,568
Liver	16,014	11,558	4,456	10,639	7,846	2,793
Gallbladder^a)	5,831	3,029	2,802	3,994	1,927	2,067
Pancreas	6,431	3,428	3,003	5,487	2,863	2,624
Larynx	1,033	1,000	33	342	339	3
Lung	25,052	16,903	8,149	17,505	12,676	4,829
Breast	20,429	73	20,356	2,452	19	2,433
Cervix uteri	3,013	-	3,013	755	-	755
Corpus uteri	2,565	-	2,565	296	-	296
Ovary	2,450	-	2,450	1,097	-	1,097
Prostate	11,062	11,062	-	1,862	1,862	-
Testis	269	269	-	19	19	-
Kidney	4,961	3,456	1,505	1,046	726	320
Bladder	3,824	3,051	773	1,412	1,076	336
Brain and CNS	1,929	1,026	903	1,160	620	540
Thyroid	45,474	11,219	34,255	360	103	257
Hodgkin lymphoma	308	199	109	69	44	25
Non-Hodgkin lymphoma	5,538	3,027	2,511	1,661	955	706
Multiple myeloma	1,555	833	722	921	510	411
Leukemia	3,223	1,822	1,401	1,760	1,015	745
Other and ill defined	16,131	8,008	8,123	4,308	2,106	2,202

CNS, central nervous system.

^a) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2.

Estimated crude and age-standardized cancer incidences by sex during 2016 in Korea

Site	Crude incidence rate per 100,000			Age-standardized incidence rate per 100,000^a)
Site	Both sexes	Male	Female	Both sexes	Male	Female
All sites	496.7	511.2	482.3	311.0	340.0	298.8
Lip, oral cavity, and pharynx	6.3	9.2	3.4	4.0	6.1	2.1
Esophagus	4.6	8.3	0.8	2.6	5.4	0.4
Stomach	66.9	91.0	42.8	39.8	59.0	23.5
Colon and rectum	74.0	91.2	56.8	43.9	59.6	30.5
Liver	31.2	45.0	17.4	18.5	29.1	9.1
Gallbladder^b)	11.4	11.8	10.9	6.2	7.6	5.0
Pancreas	12.5	13.4	11.7	7.0	8.6	5.7
Larynx	2.0	3.9	0.1	1.2	2.5	0.1
Lung	48.8	65.9	31.8	27.3	42.3	16.0
Breast	39.8	0.3	79.3	26.2	0.2	52.2
Cervix uteri	5.9	-	11.7	3.9	-	7.5
Corpus uteri	5.0	-	10.0	3.2	-	6.4
Ovary	4.8	-	9.6	3.2	-	6.4
Prostate	21.6	43.1	-	12.4	28.0	-
Testis	0.5	1.1	-	0.5	1.0	-
Kidney	9.7	13.5	5.9	6.1	8.9	3.5
Bladder	7.5	11.9	3.0	4.1	7.7	1.3
Brain and CNS	3.8	4.0	3.5	3.0	3.4	2.7
Thyroid	88.6	43.7	133.5	63.3	31.1	96.2
Hodgkin lymphoma	0.6	0.8	0.4	0.5	0.7	0.4
Non-Hodgkin lymphoma	10.8	11.8	9.8	7.4	8.6	6.3
Multiple myeloma	3.0	3.3	2.8	1.8	2.1	1.5
Leukemia	6.3	7.1	5.5	5.3	6.2	4.4
Other and ill defined	31.4	31.2	31.7	19.6	22.0	17.6

CNS, central nervous system.

^a) Age adjusted to the world standard population,

^b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3.

Estimated cancer incidence by age group and sex during 2016 in Korea

Rank	Age group (yr)
Rank	0-14	15-34	35-64	≥ 65
Male
1	Leukemia (5.0)	Thyroid (23.5)	Stomach (98.7)	Lung (434.3)
2	Non-Hodgkin lymphoma (2.6)	Colon and rectum (3.6)	Colon and rectum (96.6)	Colon and rectum (425.6)
3	Brain and CNS (2.4)	Leukemia (3.4)	Thyroid (70.1)	Stomach (418.8)
4	Liver (0.5)	Non-Hodgkin lymphoma	(3.3) Liver (54.4)	Prostate (303.5)
5	Thyroid (0.4)	Stomach (2.0)	Lung (41.9)	Liver (182.2)
Female
1	Leukemia (4.0)	Thyroid (79.7)	Thyroid (216.8)	Colon and rectum (214.6)
2	Brain and CNS (2.0)	Breast (12.0)	Breast (141.8)	Stomach (152.0)
3	Non-Hodgkin lymphoma (1.5)	Cervix uteri (5.5)	Colon and rectum (53.2)	Lung (137.0)
4	Ovary (0.8)	Stomach (3.4)	Stomach (42.5)	Thyroid (93.3)
5	Thyroid (0.7)	Ovary (3.1)	Lung (24.8)	Breast (77.7)

CNS, central nervous system.

Table 4.

Estimated crude and age-standardized cancer mortality rates by sex during 2016 in Korea

Site	Crude mortality rate per 100,000			Age-standardized mortality rate per 100,000^a)
Site	Both sexes	Male	Female	Both sexes	Male	Female
All sites	146.5	179.8	113.1	79.3	116.2	53.1
Lip, oral cavity, and pharynx	2.1	3.0	1.1	1.2	1.9	0.5
Esophagus	2.3	4.4	0.3	1.3	2.8	0.1
Stomach	13.7	17.1	10.3	7.2	11.0	4.5
Colon and rectum	17.0	20.1	13.9	8.9	13.0	6.0
Liver	20.7	30.6	10.9	11.8	19.7	5.0
Gallbladder^b)	7.8	7.5	8.1	3.9	4.8	3.3
Pancreas	10.7	11.2	10.2	5.8	7.2	4.6
Larynx	0.7	1.3	0.0	0.3	0.8	0.0
Lung	34.1	49.4	18.8	17.8	31.2	8.3
Breast	4.8	0.1	9.5	2.9	0.0	5.7
Cervix uteri	1.5	-	2.9	0.8	-	1.6
Corpus uteri	0.6	-	1.2	0.3	-	0.7
Ovary	2.1	-	4.3	1.3	-	2.4
Prostate	3.6	7.3	-	1.7	4.8	-
Testis	0.0	0.1	-	0.0	0.1	-
Kidney	2.0	2.8	1.2	1.1	1.8	0.6
Bladder	2.8	4.2	1.3	1.3	2.8	0.5
Brain and CNS	2.3	2.4	2.1	1.6	1.8	1.3
Thyroid	0.7	0.4	1.0	0.3	0.3	0.4
Hodgkin lymphoma	0.1	0.2	0.1	0.1	0.1	0.1
Non-Hodgkin lymphoma	3.2	3.7	2.8	1.8	2.4	1.3
Multiple myeloma	1.8	2.0	1.6	1.0	1.3	0.8
Leukemia	3.4	4.0	2.9	2.2	2.8	1.7
Other and ill defined	8.4	8.2	8.6	4.7	5.6	4.0

CNS, central nervous system.

^a) Age adjusted to the world standard population,

^b) Includes the gallbladder and other/unspecified parts of the biliary tract.

REFERENCES

1. Statistics Korea [Internet]. Daejeon: Statistics Korea; 2015. [cited 2016 Feb 15]. Available from: http://kosis.kr
2. Jung KW, Won YJ, Kong HJ, Oh CM, Cho H, Lee DH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat. 2015;47:127–41. Article PubMed PMC PDF
3. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999~2001; first result using the national cancer incidence database. Cancer Res Treat. 2005;37:325–31. Article PubMed PMC PDF
4. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization; 2000.
5. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. Geneva: World Health Organization; 1994.
6. Boyle P, Parkin DM. Statistical methods for registries. In: Jensen OM, Parkin DM, MacLennan R, Muir CS, Skeet RG, editors. Cancer registration: principles and methods. No. 95. Lyon: IARC; 1991. p. 126–58.
7. Australian Institute of Health and Welfare. Cancer incidence projections: Australia, 2011 to 2020. Cancer Series No. 66. Cat. No. CAN 62. Canberra: Australian Institute of Health and Welfare; 2012.
8. National Cancer Institute. Joinpoint regression program, version 4.0 [Internet]. Bethesda, MD: National Cancer Institute; 2012. c2015 [cited 2015 Jan 8]. Available from: http://surveillance.cancer.gov/joinpoint/
9. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Tohoku University School of Medicine; 1960.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Pre-transplant Dementia is Associated with Poor Survival After Hematopoietic Stem Cell Transplantation: A Nationwide Cohort Study with Propensity Score Matched Control
Sheng-Min Wang, Sung-Soo Park, See Hyun Park, Nak-Young Kim, Dong Woo Kang, Hae-Ran Na, Young-Yi Bae, Jong Wook Lee, Seunghoon Han, Hyun Kook Lim
Clinical Psychopharmacology and Neuroscience.2021; 19(2): 294. CrossRef
Improving the Subtype Classification of Non-small Cell Lung Cancer by Elastic Deformation Based Machine Learning
Yang Gao, Fan Song, Peng Zhang, Jian Liu, Jingjing Cui, Yingying Ma, Guanglei Zhang, Jianwen Luo
Journal of Digital Imaging.2021; 34(3): 605. CrossRef
Can natural killer cell activity help screen patients requiring a biopsy for the diagnosis of prostate cancer?
Bum Sik Tae, Byeong Jo Jeon, Young Hoon Lee, Hoon Choi, Jae Young Park, Jae Hyun Bae
International braz j urol.2020; 46(2): 244. CrossRef
Adolescent overweight and obesity and the risk of papillary thyroid cancer in adulthood: a large-scale case-control study
Kyoung-Nam Kim, Yunji Hwang, Kyu Hyung Kim, Kyu Eun Lee, Young Joo Park, Su-jin Kim, Hyungju Kwon, Do Joon Park, BeLong Cho, Ho-Chun Choi, Daehee Kang, Sue K. Park
Scientific Reports.2020;[Epub] CrossRef
Factors Influencing Quality of Life Among Breast Cancer Patients Following Immediate Breast Reconstruction
A Young Kim, Jeong Hye Kim
Asian Oncology Nursing.2020; 20(1): 1. CrossRef
Association between De Ritis ratio (aspartate aminotransferase/alanine aminotransferase) and oncological outcomes in bladder cancer patients after radical cystectomy
Yun-Sok Ha, Sang Won Kim, So Young Chun, Jae-Wook Chung, Seock Hwan Choi, Jun Nyung Lee, Bum Soo Kim, Hyun Tae Kim, Eun Sang Yoo, Tae Gyun Kwon, Won Tae Kim, Wun-Jae Kim, Tae-Hwan Kim
BMC Urology.2019;[Epub] CrossRef
Epigenetic inactivation of HOXD10 is associated with human colon cancer via inhibiting the RHOC/AKT/MAPK signaling pathway
Yu-hong Yuan, Han-yu Wang, Yu Lai, Wa Zhong, Wei-ling Liang, Fu-de Yan, Zhong Yu, Jun-kai Chen, Ying Lin
Cell Communication and Signaling.2019;[Epub] CrossRef
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2016
Kyu-Won Jung, Young-Joo Won, Hyun-Joo Kong, Eun Sook Lee
Cancer Research and Treatment.2019; 51(2): 417. CrossRef
Is androgen deprivation therapy associated with cerebral infarction in patients with prostate cancer? A Korean nationwide population‐based propensity score matching study
Bum Sik Tae, Byeong Jo Jeon, Hoon Choi, Jae Hyun Bae, Jae Young Park
Cancer Medicine.2019; 8(9): 4475. CrossRef
Robotic Thyroidectomy Decreases Postoperative Pain Compared With Conventional Thyroidectomy
Min Kyoung Kim, Hyun Kang, Geun Joo Choi, Kyung Ho Kang
Surgical Laparoscopy, Endoscopy & Percutaneous Techniques.2019; 29(4): 255. CrossRef
Are shape morphologies associated with survival? A potential shape-based biomarker predicting survival in lung cancer
Maliazurina Saad, Ik Hyun Lee, Tae-Sun Choi
Journal of Cancer Research and Clinical Oncology.2019; 145(12): 2937. CrossRef
The effects of BRCA1 expression on the chemosensitivity of gastric cancer cells to platinum agents
Geon Kim, Jisu Kim, Su‑Young Han, In Hwang, Hee Kim, Hyeyoung Min
Oncology Letters.2019;[Epub] CrossRef
Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients
Sumi Yun, Jiwon Koh, Soo Kyung Nam, Jung Ok Park, Sung Mi Lee, Kyoungyul Lee, Kyu Sang Lee, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Gheeyoung Choe, Woo Ho Kim, Hye Seung Lee
Gastric Cancer.2018; 21(2): 225. CrossRef
Complete cure of advanced hepatocellular carcinoma with right adrenal gland metastasis and portal vein thrombosis by multiple applications of an interdisciplinary therapy: case report with 8-year follow up
Hojung Jung, Byung Ik Kim, Yong Kyun Cho, Woo Kyu Jeon, Hong Joo Kim, Hyun Pyo Hong
Clinical and Molecular Hepatology.2018; 24(4): 424. CrossRef
Epidemiology of Intracranial Metastases in Korea: A National Cohort Investigation
Tackeun Kim, Changhoon Song, Jung Ho Han, In-Ah Kim, Yu Jung Kim, Se Hyun Kim, Jee Hyun Kim, Chae-Yong Kim
Cancer Research and Treatment.2018; 50(1): 164. CrossRef
Trend Analysis for the Choice and Cost of Lung Cancer Treatment in South Korea, 2003-2013
Dohun Kim, So Young Kim, Beomseok Suh, Jong Hyock Park
Cancer Research and Treatment.2018; 50(3): 757. CrossRef
Androgen receptor as a prognostic biomarker and therapeutic target in uterine leiomyosarcoma
Min-Hyun Baek, Jeong-Yeol Park, Yangsoon Park, Kyu-Rae Kim, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim, Joo-Hyun Nam
Journal of Gynecologic Oncology.2018;[Epub] CrossRef
Second primary colorectal cancer among endometrial cancer survivor: shared etiology and treatment sequelae
Myong Cheol Lim, Young-Joo Won, Jiwon Lim, Sang-Soo Seo, Sokbom Kang, Chong Woo Yoo, Joo-Young Kim, Jae Hwan Oh, Robert E. Bristow, Sang-Yoon Park
Journal of Cancer Research and Clinical Oncology.2018; 144(5): 845. CrossRef
Efficacy of a clinical pathway for patients with thyroid cancer
Hyungju Kwon, Joon‐Hyop Lee, Joohyun Woo, Woosung Lim, Byung‐In Moon, Nam Sun Paik
Head & Neck.2018; 40(9): 1909. CrossRef
Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01)
Bo Mi Ku, Mi Hwa Heo, Joo-Hang Kim, Byoung Chul Cho, Eun Kyung Cho, Young Joo Min, Ki Hyeong Lee, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Tae Jung Kim, Ho Yun Lee, Hojoong Kim, Kyung-Jong Lee, Myung-Ju Ahn
Journal of Pathology and Translational Medicine.2018; 52(3): 148. CrossRef
Lung Cancer Screening with Low-Dose CT in Female Never Smokers: Retrospective Cohort Study with Long-term National Data Follow-up
Hyae Young Kim, Kyu-Won Jung, Kun Young Lim, Soo-Hyun Lee, Jae Kwan Jun, Jeongseon Kim, Bin Hwangbo, Jin Soo Lee
Cancer Research and Treatment.2018; 50(3): 748. CrossRef
Treatment efficacy between total thyroidectomy and lobectomy for patients with papillary thyroid microcarcinoma: A systemic review and meta-analysis
Wuping Zheng, Jingtai Li, Pengfei Lv, Zhilin Chen, Pingming Fan
European Journal of Surgical Oncology.2018; 44(11): 1679. CrossRef
Impact of hospital care volume on clinical outcomes of laparoscopic radical hysterectomy for cervical cancer
Banghyun Lee, Kidong Kim, Youngmi Park, Myong Cheol Lim, Robert E. Bristow
Medicine.2018; 97(49): e13445. CrossRef
Relationship of Prostate-Specific Antigen Level With Obesity Indices in Korean Middle-Aged Population
Seung Ki Min, Kwibok Choi, Byoung Hoon Kim, In-Chang Cho
The Korean Journal of Urological Oncology.2018; 16(3): 103. CrossRef
Clinical significance of incidentally detected bladder wall thickening on computed tomography
Wan Song, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Han Yong Choi, Hyun Moo Lee
International Urology and Nephrology.2017; 49(2): 191. CrossRef
The association between artificial light at night and prostate cancer in Gwangju City and South Jeolla Province of South Korea
Ka Young Kim, Eunil Lee, Yun Jeong Kim, Jinsun Kim
Chronobiology International.2017; 34(2): 203. CrossRef
Use of a Combined Gene Expression Profile in Implementing a Drug Sensitivity Predictive Model for Breast Cancer
Xianglan Zhang, In-Ho Cha, Ki-Yeol Kim
Cancer Research and Treatment.2017; 49(1): 116. CrossRef
Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients
Bum Jun Kim, Changhoon Yoo, Kyu-pyo Kim, Jaewon Hyung, Seong Joon Park, Baek-Yeol Ryoo, Heung-Moon Chang
British Journal of Cancer.2017; 116(5): 561. CrossRef
Role of adjuvant radiotherapy for localized extrahepatic bile duct cancer
Yi-Jun Kim, Kyubo Kim, Seog Ki Min, Eun Mi Nam
The British Journal of Radiology.2017;[Epub] CrossRef
Molecular Testing for Gastrointestinal Cancer
Hye Seung Lee, Woo Ho Kim, Yoonjin Kwak, Jiwon Koh, Jeong Mo Bae, Kyoung-Mee Kim, Mee Soo Chang, Hye Seung Han, Joon Mee Kim, Hwal Woong Kim, Hee Kyung Chang, Young Hee Choi, Ji Y. Park, Mi Jin Gu, Min Jin Lhee, Jung Yeon Kim, Hee Sung Kim, Mee-Yon Cho
Journal of Pathology and Translational Medicine.2017; 51(2): 103. CrossRef
Endoscopic Thyroidectomy Via the Cervico-axillary Approach for Thyroid Cancer: Initial Experience in a Single Institute
Jeong Shin An, Hyun Goo Kim, Se Hyun Paek, Jun Woo Lee, Juhyun Woo, Hyungju Kwon, Woosung Lim, Byung-In Moon, Nam Sun Paik
Korean Journal of Endocrine Surgery.2017; 17(1): 19. CrossRef
Endoscopic Thyroidectomy Via the Cervico-axillary Approach for Thyroid Cancer: Initial Experience in a Single Institute
Jeong Shin An, Hyun Goo Kim, Se Hyun Paek, Jun Woo Lee, Juhyun Woo, Hyungju Kwon, Woosung Lim, Byung-In Moon, Nam Sun Paik
Korean Journal of Endocrine Surgery.2017; 17(1): 19. CrossRef
The Effect of Post-operative Exercise in Colorectal Cancer Patients: A Pilot Randomized Controlled Trial (RCT) Study
Ji-hee Min, Ki-yong Ahn, Hyuna Park, Wonhee Cho, Hye Jeong Jung, Nam Kyu Kim, Justin Y Jeon
Asian Oncology Nursing.2017; 17(1): 29. CrossRef
Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer
Myong Cheol Lim, Heong Jong Yoo, Yong Jung Song, Sang-Soo Seo, Sokbom Kang, Sun Ho Kim, Chong Woo Yoo, Sang-Yoon Park
Journal of Gynecologic Oncology.2017;[Epub] CrossRef
Malignancies in Korean patients with immunoglobulin G4‐related disease
Sung Soo Ahn, Jason Jungsik Song, Yong‐Beom Park, Sang‐Won Lee
International Journal of Rheumatic Diseases.2017; 20(8): 1028. CrossRef
Do hepatic-sided tumors require more extensive resection than peritoneal-sided tumors in patients with T2 gallbladder cancer? Results of a retrospective multicenter study
Woohyung Lee, Chi-Young Jeong, Jae Yool Jang, Young Hoon Kim, Young Hoon Roh, Kwan Woo Kim, Sung Hwa Kang, Myung Hee Yoon, Hyung Il Seo, Sung Pil Yun, Jeong-Ik Park, Bo-Hyun Jung, Dong Hoon Shin, Young Il Choi, Hyung Hwan Moon, Chong Woo Chu, Je Ho Ryu, K
Surgery.2017; 162(3): 515. CrossRef
The prognostic value of BAP1, PBRM1, pS6, PTEN, TGase2, PD-L1, CA9, PSMA, and Ki-67 tissue markers in localized renal cell carcinoma: A retrospective study of tissue microarrays using immunohistochemistry
Sung Han Kim, Weon Seo Park, Eun Young Park, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung, Jung Weon Lee
PLOS ONE.2017; 12(6): e0179610. CrossRef
Differential proteome expression analysis of androgen-dependent and -independent pathways in LNCaP prostate cancer cells
Seho Cha, Dong Hoon Shin, Jun Ryeong Seok, Jae Kyung Myung
Experimental Cell Research.2017; 359(1): 215. CrossRef
Cholecystectomy can increase the risk of colorectal cancer: A meta-analysis of 10 cohort studies
Yong Zhang, Hao Liu, Li Li, Min Ai, Zheng Gong, Yong He, Yunlong Dong, Shuanglan Xu, Jun Wang, Bo Jin, Jianping Liu, Zhaowei Teng, Nathan A. Ellis
PLOS ONE.2017; 12(8): e0181852. CrossRef
Estimated future incidence of malignant mesothelioma in South Korea: Projection from 2014 to 2033
Kyeong Min Kwak, Domyung Paek, Seung-sik Hwang, Young-Su Ju, Mark Allen Pershouse
PLOS ONE.2017; 12(8): e0183404. CrossRef
A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients
Aryo D. Pamungkas, Carl A. Medriano, Eunjung Sim, Sungyong Lee, Youngja H. Park
Molecular Medicine Reports.2017; 15(6): 4155. CrossRef
Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries
Martin C. S. Wong, William B. Goggins, Benjamin H. K. Yip, Franklin D. H. Fung, Colette Leung, Yuan Fang, Samuel Y. S. Wong, C. F. Ng
Scientific Reports.2017;[Epub] CrossRef
Exercise Perception during Hematopoietic Transplantation for Hematological Cancer Patients
Mi-seong Yu, Ji Yong Byeon, Ki-Yong An, Meeok Choi, June-Won Cheong, Justin Y. Jeon
The Korean Journal of Physical Education.2017; 56(6): 527. CrossRef
Telomere length is correlated with mitochondrial DNA copy number in intestinal, but not diffuse, gastric cancer
Soo-Jung Jung, Ji-Hyoung Cho, Won-Jin Park, Yu-Ran Heo, Jae-Ho Lee
Oncology Letters.2017; 14(1): 925. CrossRef
Diabetes Mellitus Increases the Risk of Intrahepatic Recurrence of Hepatocellular Carcinoma after Surgical Resection
Yunseon Choi, YoungKil Choi, Chang Soo Choi, Yun-Han Lee
Tumori Journal.2017; 103(3): 279. CrossRef
Prognostic impact offibroblast growth factor receptor 2gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers
Seyoung Seo, Seong Joon Park, Min-Hee Ryu, Sook Ryun Park, Baek-Yeol Ryoo, Young Soo Park, Young-Soon Na, Chae-Won Lee, Ju-Kyung Lee, Yoon-Koo Kang
Oncotarget.2017; 8(20): 33844. CrossRef
Programmed death ligand-1 and MET co-expression is a poor prognostic factor in gastric cancers after resection
Mi Jung Kwon, Kab-Choong Kim, Eun Sook Nam, Seong Jin Cho, Hye-Rim Park, Soo Kee Min, Jinwon Seo, Ji-Young Choe, Hye Kyung Lee, Ho Suk Kang, Kyueng-Whan Min
Oncotarget.2017; 8(47): 82399. CrossRef
Risk factors for feelings of sadness and suicide attempts among cancer survivors in South Korea: findings from nationwide cross-sectional study (KNHANES IV–VI)
Jeewoong Choi, Mijo Lee, Myung Ki, Ju-Yeong Lee, Yeong-Jun Song, Miram Kim, Sunyoung Lee, Soonjoo Park, Jiseun Lim
BMJ Open.2017; 7(12): e016130. CrossRef
Bacillusspp. orBacillusspp.-Derived Membrane Vesicles Induce the Intrinsic Pathways of Apoptosis of Human Colon Cancer Cell Lines
Miso Yang, In-Taek Jang, Hwa-Jung Kim, Jeong-Kyu Park
Journal of Bacteriology and Virology.2016; 46(2): 84. CrossRef
Anti-proliferation Effect of Coscinoderma sp. Extract on Human Colon Cancer Cells
Ki Heon Choi, Joohee Jung
Journal of Food Hygiene and Safety.2016; 31(4): 294. CrossRef
Pregnancy-Associated Risk Factors of Postpartum Breast Cancer in Korea: A Nationwide Health Insurance Database Study
Eun Joo Kang, Jae Hong Seo, Log Young Kim, Geun U. Park, Min-Jeong Oh, Pyoung-Jae Park, Geum Joon Cho, Pal Bela Szecsi
PLOS ONE.2016; 11(12): e0168469. CrossRef
The Correlation of Tissue-Based Biomarkers in Primary and Metastatic Renal Cell Carcinoma Lesions: A Tissue Microarray Study
Sung Han Kim, Weon Seo Park, Eun Young Park, Boram Park, Jungnam Joo, Jae Young Joung, Ho Kyung Seo, Kang Hyun Lee, Jinsoo Chung
The Korean Journal of Urological Oncology.2016; 14(3): 152. CrossRef
Interleukin-10 Polymorphisms in Association with Prognosis in Patients with B-Cell Lymphoma Treated by R-CHOP
Min Kyeong Kim, Kyong-Ah Yoon, Eun Young Park, Jungnam Joo, Eun Young Lee, Hyeon-Seok Eom, Sun-Young Kong
Genomics & Informatics.2016; 14(4): 205. CrossRef
Anxiety and Depression as Predictive Factors for Quality of Life in Patients with Advanced Gastrointestinal Cancer
JungHwa Chung, Jihyun Kwon, Hyun Kyung Kim, Gawon Ju, Seung Taik Kim, Hye Sook Han
Asian Oncology Nursing.2016; 16(4): 242. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Prediction of Cancer Incidence and Mortality in Korea, 2016

Cancer Res Treat. 2016;48(2):451-457. Published online March 25, 2016

DOI: https://doi.org/10.4143/crt.2016.092

XML Download

Abstract
Introduction
Materials and Methods
Results
Conclusion
NOTES
REFERENCES

Prediction of Cancer Incidence and Mortality in Korea, 2016

Fig. 1. The 10 leading types of estimated new cancer cases and deaths by sex in 2016. (A) Estimated new cases. (B) Estimated deaths.

Fig. 2. Projected age-specific incidences of major cancers during 2016 in Korea. (A) Male. (B) Female.

Fig. 3. Projected age-specific mortality rates of major cancers during 2016 in Korea. (A) Male. (B) Female.

Fig. 1.

Fig. 2.

Fig. 3.

Prediction of Cancer Incidence and Mortality in Korea, 2016

Site	Estimated new cases			Estimated deaths
Site	Both sexes	Male	Female	Both sexes	Male	Female
All sites	254,962	131,224	123,738	75,172	46,155	29,017
Lip, oral cavity, and pharynx	3,236	2,363	873	1,059	775	284
Esophagus	2,335	2,137	198	1,199	1,125	74
Stomach	34,331	23,355	10,976	7,054	4,402	2,652
Colon and rectum	37,968	23,406	14,562	8,715	5,147	3,568
Liver	16,014	11,558	4,456	10,639	7,846	2,793
Gallbladder^a)	5,831	3,029	2,802	3,994	1,927	2,067
Pancreas	6,431	3,428	3,003	5,487	2,863	2,624
Larynx	1,033	1,000	33	342	339	3
Lung	25,052	16,903	8,149	17,505	12,676	4,829
Breast	20,429	73	20,356	2,452	19	2,433
Cervix uteri	3,013	-	3,013	755	-	755
Corpus uteri	2,565	-	2,565	296	-	296
Ovary	2,450	-	2,450	1,097	-	1,097
Prostate	11,062	11,062	-	1,862	1,862	-
Testis	269	269	-	19	19	-
Kidney	4,961	3,456	1,505	1,046	726	320
Bladder	3,824	3,051	773	1,412	1,076	336
Brain and CNS	1,929	1,026	903	1,160	620	540
Thyroid	45,474	11,219	34,255	360	103	257
Hodgkin lymphoma	308	199	109	69	44	25
Non-Hodgkin lymphoma	5,538	3,027	2,511	1,661	955	706
Multiple myeloma	1,555	833	722	921	510	411
Leukemia	3,223	1,822	1,401	1,760	1,015	745
Other and ill defined	16,131	8,008	8,123	4,308	2,106	2,202

Site	Crude incidence rate per 100,000			Age-standardized incidence rate per 100,000^a)
Site	Both sexes	Male	Female	Both sexes	Male	Female
All sites	496.7	511.2	482.3	311.0	340.0	298.8
Lip, oral cavity, and pharynx	6.3	9.2	3.4	4.0	6.1	2.1
Esophagus	4.6	8.3	0.8	2.6	5.4	0.4
Stomach	66.9	91.0	42.8	39.8	59.0	23.5
Colon and rectum	74.0	91.2	56.8	43.9	59.6	30.5
Liver	31.2	45.0	17.4	18.5	29.1	9.1
Gallbladder^b)	11.4	11.8	10.9	6.2	7.6	5.0
Pancreas	12.5	13.4	11.7	7.0	8.6	5.7
Larynx	2.0	3.9	0.1	1.2	2.5	0.1
Lung	48.8	65.9	31.8	27.3	42.3	16.0
Breast	39.8	0.3	79.3	26.2	0.2	52.2
Cervix uteri	5.9	-	11.7	3.9	-	7.5
Corpus uteri	5.0	-	10.0	3.2	-	6.4
Ovary	4.8	-	9.6	3.2	-	6.4
Prostate	21.6	43.1	-	12.4	28.0	-
Testis	0.5	1.1	-	0.5	1.0	-
Kidney	9.7	13.5	5.9	6.1	8.9	3.5
Bladder	7.5	11.9	3.0	4.1	7.7	1.3
Brain and CNS	3.8	4.0	3.5	3.0	3.4	2.7
Thyroid	88.6	43.7	133.5	63.3	31.1	96.2
Hodgkin lymphoma	0.6	0.8	0.4	0.5	0.7	0.4
Non-Hodgkin lymphoma	10.8	11.8	9.8	7.4	8.6	6.3
Multiple myeloma	3.0	3.3	2.8	1.8	2.1	1.5
Leukemia	6.3	7.1	5.5	5.3	6.2	4.4
Other and ill defined	31.4	31.2	31.7	19.6	22.0	17.6

Rank	Age group (yr)
Rank	0-14	15-34	35-64	≥ 65
Male
1	Leukemia (5.0)	Thyroid (23.5)	Stomach (98.7)	Lung (434.3)
2	Non-Hodgkin lymphoma (2.6)	Colon and rectum (3.6)	Colon and rectum (96.6)	Colon and rectum (425.6)
3	Brain and CNS (2.4)	Leukemia (3.4)	Thyroid (70.1)	Stomach (418.8)
4	Liver (0.5)	Non-Hodgkin lymphoma	(3.3) Liver (54.4)	Prostate (303.5)
5	Thyroid (0.4)	Stomach (2.0)	Lung (41.9)	Liver (182.2)
Female
1	Leukemia (4.0)	Thyroid (79.7)	Thyroid (216.8)	Colon and rectum (214.6)
2	Brain and CNS (2.0)	Breast (12.0)	Breast (141.8)	Stomach (152.0)
3	Non-Hodgkin lymphoma (1.5)	Cervix uteri (5.5)	Colon and rectum (53.2)	Lung (137.0)
4	Ovary (0.8)	Stomach (3.4)	Stomach (42.5)	Thyroid (93.3)
5	Thyroid (0.7)	Ovary (3.1)	Lung (24.8)	Breast (77.7)

Site	Crude mortality rate per 100,000			Age-standardized mortality rate per 100,000^a)
Site	Both sexes	Male	Female	Both sexes	Male	Female
All sites	146.5	179.8	113.1	79.3	116.2	53.1
Lip, oral cavity, and pharynx	2.1	3.0	1.1	1.2	1.9	0.5
Esophagus	2.3	4.4	0.3	1.3	2.8	0.1
Stomach	13.7	17.1	10.3	7.2	11.0	4.5
Colon and rectum	17.0	20.1	13.9	8.9	13.0	6.0
Liver	20.7	30.6	10.9	11.8	19.7	5.0
Gallbladder^b)	7.8	7.5	8.1	3.9	4.8	3.3
Pancreas	10.7	11.2	10.2	5.8	7.2	4.6
Larynx	0.7	1.3	0.0	0.3	0.8	0.0
Lung	34.1	49.4	18.8	17.8	31.2	8.3
Breast	4.8	0.1	9.5	2.9	0.0	5.7
Cervix uteri	1.5	-	2.9	0.8	-	1.6
Corpus uteri	0.6	-	1.2	0.3	-	0.7
Ovary	2.1	-	4.3	1.3	-	2.4
Prostate	3.6	7.3	-	1.7	4.8	-
Testis	0.0	0.1	-	0.0	0.1	-
Kidney	2.0	2.8	1.2	1.1	1.8	0.6
Bladder	2.8	4.2	1.3	1.3	2.8	0.5
Brain and CNS	2.3	2.4	2.1	1.6	1.8	1.3
Thyroid	0.7	0.4	1.0	0.3	0.3	0.4
Hodgkin lymphoma	0.1	0.2	0.1	0.1	0.1	0.1
Non-Hodgkin lymphoma	3.2	3.7	2.8	1.8	2.4	1.3
Multiple myeloma	1.8	2.0	1.6	1.0	1.3	0.8
Leukemia	3.4	4.0	2.9	2.2	2.8	1.7
Other and ill defined	8.4	8.2	8.6	4.7	5.6	4.0

Table 1. Estimated new cancer cases and deaths by sex during 2016 in Korea

CNS, central nervous system.

Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 2. Estimated crude and age-standardized cancer incidences by sex during 2016 in Korea

CNS, central nervous system.

Age adjusted to the world standard population,

Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3. Estimated cancer incidence by age group and sex during 2016 in Korea

CNS, central nervous system.

Table 4. Estimated crude and age-standardized cancer mortality rates by sex during 2016 in Korea

CNS, central nervous system.

Age adjusted to the world standard population,

Includes the gallbladder and other/unspecified parts of the biliary tract.